Trilaciclib

About Chemogenics BioPharma

ChemoGenics BioPharma operates as a preclinical-stage contract research organization (CRO) and drug discovery partner, offering a full suite of services from custom synthesis and medicinal chemistry to in vitro ADME and in vivo PK/PD studies. The company's core strength lies in its team of PhD scientists with over 10+ years of industry experience, enabling them to deliver intellectual property and support clients from target identification to clinical candidate selection. While primarily a service provider, the company's leadership has a proven track record in drug discovery, having invented the commercially marketed CDK4/6 inhibitor Trilaciclib and advanced Lerociclib to Phase 3 trials. Their strategic focus is on being a cost-effective, one-stop partner for managing escalating R&D costs while protecting client IP.

Therapeutic Areas